

Klaus Olgaard

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10427043/publications.pdf>

Version: 2024-02-01

75
papers

3,023
citations

201674

27
h-index

168389

53
g-index

77
all docs

77
docs citations

77
times ranked

3125
citing authors

#	ARTICLE	IF	CITATIONS
1	Vitamin D controls T cell antigen receptor signaling and activation of human T cells. <i>Nature Immunology</i> , 2010, 11, 344-349.	14.5	493
2	Bone mineral density and biochemical markers of bone turnover in patients with predialysis chronic renal failure. <i>Kidney International</i> , 1999, 56, 1084-1093.	5.2	270
3	Diagnosis, assessment, and treatment of bone turnover abnormalities in renal osteodystrophy. <i>American Journal of Kidney Diseases</i> , 2004, 43, 558-565.	1.9	147
4	Chronic Renal Failure Accelerates Atherogenesis in Apolipoprotein E-deficient Mice. <i>Journal of the American Society of Nephrology: JASN</i> , 2003, 14, 2466-2474.	6.1	138
5	Effects of excess PTH on nonclassical target organs. <i>American Journal of Kidney Diseases</i> , 1997, 30, 606-620.	1.9	118
6	Impaired kidney growth in low-birth-weight children: Distinct effects of maturity and weight for gestational age. <i>Kidney International</i> , 2005, 68, 731-740.	5.2	95
7	Abnormal Bone and Mineral Metabolism in Kidney Transplant Patients – A Review. <i>American Journal of Nephrology</i> , 2008, 28, 246-253.	3.1	71
8	Bone mineral content by photon absorptiometry of the mandible compared with that of the forearm and the lumbar spine. <i>Calcified Tissue International</i> , 1988, 42, 157-161.	3.1	68
9	Increased Expression of Adhesion Molecules in Uremic Atherosclerosis in Apolipoprotein-E-Deficient Mice. <i>Journal of the American Society of Nephrology: JASN</i> , 2004, 15, 1495-1503.	6.1	68
10	Effect of 18 months of treatment with alfacalcidol on bone in patients with mild to moderate chronic renal failure. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, 870-876.	0.7	67
11	Increased parathyroid expression of klotho in uremic rats. <i>Kidney International</i> , 2010, 78, 1119-1127.	5.2	63
12	A direct effect in vitro of phosphate on PTH release from bovine parathyroid tissue slices but not from dispersed parathyroid cells. <i>Nephrology Dialysis Transplantation</i> , 1996, 11, 1762-1768.	0.7	59
13	Key role of the kidney in the regulation of fibroblast growth factor 23. <i>Kidney International</i> , 2015, 88, 1304-1313.	5.2	57
14	Effect of 1,25-dihydroxy-vitamin D ₃ in experimental sepsis. <i>International Journal of Medical Sciences</i> , 2007, 4, 190-195.	2.5	57
15	Persistent Downregulation of Calcium-Sensing Receptor mRNA in Rat Parathyroids when Severe Secondary Hyperparathyroidism Is Reversed by an Isogenic Kidney Transplantation. <i>Journal of the American Society of Nephrology: JASN</i> , 2002, 13, 2110-2116.	6.1	54
16	Kidney growth in 717 healthy children aged 0;½months: a longitudinal cohort study. <i>Pediatric Nephrology</i> , 2004, 19, 992-1003.	1.7	47
17	Steroid-induced mandibular bone loss in relation to marginal periodontal changes. <i>Journal of Clinical Periodontology</i> , 1992, 19, 182-186.	4.9	46
18	Effect of chronic uremia on the transcriptional profile of the calcified aorta analyzed by RNA sequencing. <i>American Journal of Physiology - Renal Physiology</i> , 2016, 310, F477-F491.	2.7	45

#	ARTICLE	IF	CITATIONS
19	Reversibility of experimental secondary hyperparathyroidism. <i>Kidney International</i> , 1997, 52, 1232-1241.	5.2	43
20	Increased kidney growth in formula-fed versus breast-fed healthy infants. <i>Pediatric Nephrology</i> , 2004, 19, 1137-44.	1.7	43
21	Parathyroid Hormone 7-84 Induces Hypocalcemia and Inhibits the Parathyroid Hormone 1-84 Secretory Response to Hypocalcemia in Rats with Intact Parathyroid Glands. <i>Journal of the American Society of Nephrology: JASN</i> , 2006, 17, 1923-1930.	6.1	42
22	A neutralizing antibody against receptor for advanced glycation end products (RAGE) reduces atherosclerosis in uremic mice. <i>Atherosclerosis</i> , 2008, 201, 274-280.	0.8	42
23	Kidney fibroblast growth factor 23 does not contribute to elevation of its circulating levels in uremia. <i>Kidney International</i> , 2017, 92, 165-178.	5.2	42
24	Pharmacokinetics of 1,25(OH)2D3 and 1alpha(OH)D3 in normal and uraemic men. <i>Nephrology Dialysis Transplantation</i> , 2002, 17, 829-842.	0.7	41
25	New Aspects of the Kidney in the Regulation of Fibroblast Growth Factor 23 (FGF23) and Mineral Homeostasis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8810.	4.1	35
26	Uremia-Specific Effects in the Arterial Media During Development of Uremic Atherosclerosis in Apolipoprotein E-Deficient Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2006, 26, 570-575.	2.4	29
27	Fibroblast Growth Factor (FGF) 23 Regulates the Plasma Levels of Parathyroid Hormone In Vivo Through the FGF Receptor in Normocalcemia, But Not in Hypocalcemia. <i>Calcified Tissue International</i> , 2018, 102, 85-92.	3.1	29
28	Inhibition of the Renin-Angiotensin System Abolishes the Proatherogenic Effect of Uremia in Apolipoprotein E-Deficient Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2007, 27, 1080-1086.	2.4	28
29	PTHrP enhances the secretory response of PTH to a hypocalcemic stimulus in rat parathyroid glands. <i>Kidney International</i> , 2000, 58, 71-81.	5.2	26
30	Klotho and activin A in kidney injury: plasma Klotho is maintained in unilateral obstruction despite no upregulation of Klotho biosynthesis in the contralateral kidney. <i>American Journal of Physiology - Renal Physiology</i> , 2018, 314, F753-F762.	2.7	26
31	High dose intravenous iron, mineral homeostasis and intact FGF23 in normal and uremic rats. <i>BMC Nephrology</i> , 2013, 14, 281.	1.8	25
32	Ergocalciferol treatment and aspects of mineral homeostasis in patients with chronic kidney disease stage 4-5. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2013, 73, 107-116.	1.2	25
33	Effect of Intravenous 1-Alpha-Hydroxyvitamin D ₃ on Secondary Hyperparathyroidism in Chronic Uremic Patients on Maintenance Hemodialysis. <i>Nephron</i> , 1989, 53, 194-200.	1.8	24
34	Parathyroidectomy vs calcimimetics for treatment of persistent hyperparathyroidism after kidney transplantation. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 1766-1769.	0.7	24
35	The vascular secret of Klotho. <i>Kidney International</i> , 2015, 87, 1089-1091.	5.2	24
36	Chronic Kidney Disease-Induced Vascular Calcification Impairs Bone Metabolism. <i>Journal of Bone and Mineral Research</i> , 2020, 36, 510-522.	2.8	24

#	ARTICLE	IF	CITATIONS
37	The calcium/parathyroid hormone concept of the parathyroid glands. <i>Current Opinion in Nephrology and Hypertension</i> , 1995, 4, 324-333.	2.0	22
38	Circadian rhythm of activin A and related parameters of mineral metabolism in normal and uremic rats. <i>Pflugers Archiv European Journal of Physiology</i> , 2019, 471, 1079-1094.	2.8	22
39	Parathyroid hormone dependent T cell proliferation in uremic rats. <i>Kidney International</i> , 1993, 44, 379-384.	5.2	21
40	Autoregulation in the parathyroid glands by PTH/PTHrP receptor ligands in normal and uremic rats. <i>Kidney International</i> , 2003, 64, 63-70.	5.2	21
41	Prevention of Uremic Bone Disease Using Calcimimetic Compounds. <i>Annual Review of Medicine</i> , 2001, 52, 203-220.	12.2	20
42	Effect of parathyroid hormone on renal calbindin-D28k. <i>Journal of Bone and Mineral Research</i> , 1996, 11, 1086-1093.	2.8	20
43	A molecular circadian clock operates in the parathyroid gland and is disturbed in chronic kidney disease associated bone and mineral disorder. <i>Kidney International</i> , 2020, 98, 1461-1475.	5.2	20
44	Influence of Calcium on the Metabolism of Intact Parathyroid Hormone by Isolated Perfused Rat Kidney and Liver*. <i>Endocrinology</i> , 1990, 126, 1813-1820.	2.8	19
45	Posttransplant bone disease. <i>Transplantation Reviews</i> , 2003, 17, 176-186.	2.9	19
46	Effect of NAD+ boosting on kidney ischemia-reperfusion injury. <i>PLoS ONE</i> , 2021, 16, e0252554.	2.5	19
47	Effect of 24,25(OH)2D3 on PTH levels and bone histology in dogs with chronic uremia. <i>Kidney International</i> , 1984, 26, 791-797.	5.2	17
48	A potential kidney - bone axis involved in the rapid minute-to-minute regulation of plasma Ca ²⁺ . <i>BMC Nephrology</i> , 2015, 16, 29.	1.8	17
49	Circadian rhythms of mineral metabolism in chronic kidney disease—mineral bone disorder. <i>Current Opinion in Nephrology and Hypertension</i> , 2020, 29, 367-377.	2.0	17
50	Exogenous BMP7 in aortae of rats with chronic uremia ameliorates expression of profibrotic genes, but does not reverse established vascular calcification. <i>PLoS ONE</i> , 2018, 13, e0190820.	2.5	17
51	Basic Science and Dialysis: Parathyroid Growth and Suppression in Renal Failure. <i>Seminars in Dialysis</i> , 2006, 19, 238-245.	1.3	16
52	Circulating FGF23 Levels in Response to Acute Changes in Plasma Ca ²⁺ . <i>Calcified Tissue International</i> , 2014, 95, 46-53.	3.1	16
53	The secretory response of parathyroid hormone to acute hypocalcemia in vivo is independent of parathyroid glandular sodium/potassium-ATPase activity. <i>Kidney International</i> , 2011, 79, 742-748.	5.2	15
54	Klotho, an important new factor for the activity of Ca ²⁺ channels, connecting calcium homeostasis, ageing and uraemia. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 1770-1772.	0.7	14

#	ARTICLE	IF	CITATIONS
55	Cardiac structure and function in a mouse model of uraemia without hypertension. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2008, 68, 660-666.	1.2	14
56	1,25(OH) ₂ D ₃ only affects long-term levels of plasma Ca ²⁺ but not the rapid minute-to-minute plasma Ca ²⁺ homeostasis in the rat. <i>Steroids</i> , 1999, 64, 726-734.	1.8	12
57	Use (or misuse) of vitamin D treatment in CKD and dialysis patients: A recent meta-analysis on vitamin D compounds in chronic kidney disease [1] and an editorial comment [2] accompanying this meta-analysis have already been published. We believe that these papers deserve some comments in the interest of the NDT readership. <i>Nephrology Dialysis Transplantation</i> , 2008, 23, 1786-1789.	0.7	12
58	Effect of inhibition of CBP-coactivated β -catenin-mediated Wnt signalling in uremic rats with vascular calcifications. <i>PLoS ONE</i> , 2018, 13, e0201936.	2.5	11
59	Epigenetic Methylation of Parathyroid <i>CaR</i> and <i>VDR</i> Promoters in Experimental Secondary Hyperparathyroidism. <i>International Journal of Nephrology</i> , 2012, 2012, 1-9.	1.3	10
60	Can Hyperparathyroid Bone Disease Be Arrested or Reversed?. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2006, 1, 367-373.	4.5	9
61	Impaired Vitamin D Signaling in T Cells From a Family With Hereditary Vitamin D Resistant Rickets. <i>Frontiers in Immunology</i> , 2021, 12, 684015.	4.8	8
62	New Insights to the Crosstalk between Vascular and Bone Tissue in Chronic Kidney Disease—Mineral and Bone Disorder. <i>Metabolites</i> , 2021, 11, 849.	2.9	8
63	Hypomorphic expression of parathyroid <i>Bmal1</i> disrupts the internal parathyroid circadian clock and increases parathyroid cell proliferation in response to uremia. <i>Kidney International</i> , 2022, 101, 1232-1250.	5.2	8
64	Metabolism of Prednisone in Kidney Transplanted Patients with Necrosis of the Femoral Head. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1993, 72, 78-83.	0.0	7
65	Separate Effects of 1,25-Dihydroxyvitamin D and Calcium on Renal Calbindin-D28k and Intestinal Calbindin-D9k. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2002, 91, 111-115.	0.0	7
66	Diurnal variation of magnesium and the mineral metabolism in patients with chronic kidney disease. <i>Bone Reports</i> , 2021, 15, 101130.	0.4	7
67	Calcium metabolic changes and calbindin-D in experimental hypertension. <i>Journal of Hypertension</i> , 1994, 12, 901-908.	0.5	6
68	The Effect of 1,25-Dihydroxyvitamin D ₃ on Calbindin-D _{9k} and Calcium Metabolic Variables in the Rat. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1998, 82, 118-121.	0.0	6
69	Parathyroid hormone-related peptide plasma concentrations in patients on hemodialysis. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2014, 74, 206-212.	1.2	6
70	The Vascular Circadian Clock in Chronic Kidney Disease. <i>Cells</i> , 2021, 10, 1769.	4.1	5
71	Lack of influence of 24,25-dihydroxyvitamin D ₃ on parathyroid hormone secretion from normal or hyperplastic glands. <i>Calcified Tissue International</i> , 1983, 35, 449-454.	3.1	4
72	Comparison between 1 α (OH)D ₃ and 1,25(OH) ₂ D ₃ on the Suppression of Plasma PTH Levels in Uremic Patients, Evaluated by the α -Whole TM and α -Intact TM PTH Assays. <i>Nephron Clinical Practice</i> , 2005, 99, c128-c137.	2.3	4

#	ARTICLE	IF	CITATIONS
73	The Calcified Vasculature in Chronic Kidney Disease Secretes Factors that Inhibit Bone Mineralization. <i>JBMR Plus</i> , 2022, 6, e10610.	2.7	3
74	<i>Opinion</i> : When is Vitamin D Contraindicated in Dialysis Patients?. <i>Seminars in Dialysis</i> , 2009, 22, 240-242.	1.3	2
75	Reply to Dr S.C. Palmer and co-workers. <i>Nephrology Dialysis Transplantation</i> , 2008, 23, 2709-2710.	0.7	1